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Abstract
Background: Therapeutic progress in patients with cystic fibrosis (CF) has resulted in improved prognosis over the past decades. We aim to
reevaluate prognostic factors of CF and provide a prognostic score to predict the risk of death or lung transplantation (LT) within a 3-year period in
adult patients.
Methods: We developed a logistic model using data from the French CF Registry and combined the coefficients into a prognostic score. The
discriminative abilities of the model and the prognostic score were assessed by c-statistic. The prognostic score was validated using a 10-fold cross-
validation.
Results: The risk of death or LT within 3 years was related to eight characteristics. The development and the validation provided excellent results
for the prognostic score; the c-statistic was 0.91 and 0.90 respectively.
Conclusion: The score developed to predict 3-year death or LT in adults with CF might be useful for clinicians to identify patients requiring
specialized evaluation for LT.
© 2017 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Cystic fibrosis; Prognostic factors; Registry data; Logistic model; Prognostic score1. Introduction
Cystic fibrosis (CF) is a multiorgan disease that affects
primarily the lungs, causing diffuse bronchiectasis which often
leads to progressive respiratory insufficiency and premature
death [9]. Lung transplantation (LT) is proposed to CF patients
with terminal respiratory failure with the aim of improving life
expectancy and quality of life [25]. Although criteria for referringpatients for LT have been proposed [14], the optimal timing for
referring CF patients for transplantation remains difficult to
establish in an individual patient. A recent study in France has
shown that respiratory death in CF patients often occurs due to
late or no referral for LT [19], suggesting the need to develop
novel strategies for referring patients at high risk of death for
transplant evaluation.
In the past 25 years, several statistical models have been
developed to identify prognostic factors in CF patients. In their
seminal study, Kerem et al. identified forced expiratory volume
in 1 s (FEV1) as the main prognostic factor and suggested that
patients with an FEV1 value less than 30% should be considered
for LT [16]. Subsequent studies identified multiple other factors
related to death in patients with CF including older age [17,21],e CC BY-NC-ND
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pancreatic insufficiency [1,17], diabetes [1,17], Pseudomonas
aeruginosa colonization [1,6], Burkholderia cepacia colonization
[4,6,17], Staphylococcus aureus colonization [7], massive hemop-
tysis [11], pneumothorax [10] and high number of pulmonary
exacerbations [4,17,21]. Although several attempts at developing
prognostic scores have been performed in CF patients
[1,4,13,17,20,21], it has proven difficult to develop a score that
better predicts death than FEV1 b 30% predicted [20]. Further,
prognosis has dramatically improved over the past decades due to
advance in integrated care provided by multidisciplinary teams in
CF centers [2,8,12,18,23]. As a result, prognostic factors have
changed over time and studies performed using data obtained in
previous decades may not be appropriate for current evaluation of
CF patients. For example, George et al. showed an important
improvement in the survival of patients whose FEV1 has fallen
below 30% of predicted value. Consequently, they suggested that
the threshold of 30% predicted for FEV1 should no longer be
considered in isolation as an indication for LT [12]. Moreover,
pediatric mortality in patients with CF has almost disappeared in
developed countries due to improvement in patients care by
multidisciplinary teams [26].
The aim of the present study was to develop a 3-year
predictive model that provides a prognostic score to better
predict the risk of death or LT in adult patients with CF.2. Materials and methods
2.1. The French Cystic Fibrosis Registry
We used data from the French Cystic Fibrosis Registry (French
CF Registry). This registry contains longitudinal data on more
than 8000 patients since 1992, which represents approximately
90% of all CF patients in France [3]. Each patient is assigned to a
center specialized in CF, where his/her health status is regularly
monitored. A numeric code is assigned to each patient to link
information between specialized centers and the French CF
Registry. This registry records annual health-check data for each
subject including vital status, therapeutic management, anthro-
pometry, spirometry, morbidity factors, consultations and hospi-
talizations, arterial blood gas, microbiological tests, pregnancy
and paternity, and transplantations and sociodemographic data [3].2.2. Patients and data collection
The period of the study was 2010–2013. Patients alive and
aged 18 years or older on 31st December 2010 and for whom
vital status was known on 31st December 2013 were included in
the study. Patients who received a lung transplant before 2010
and patients lost to follow-up between 2011 and 2013 were
excluded from the study. Forty-two covariates (listed in Table 1
and Supplementary Table 1) considered as potential predictors
and records of the year 2010 were extracted to predict the
outcome, defined as death or LT before the end of 2013. Fig. 1
presents the selection scheme of patients who were included in
the study.2.3. Missing data imputation
In 2010, only 12% of patients had complete information for
all the 42 potential predictors. However, the percentage of
missing data represented only 4%, as illustrated in Table 1. To
deal with missing data in the covariates, a multiple imputation
by chained equations was used [27]. We assumed that data
were missing at random that is, the probability of missingness
depends on the values of the observed covariates.
2.4. Model development
The characteristics of patients according to the outcome were
compared using chi-square test or Fisher's exact test for
categorical variables, and the Mann–Whitney test for continuous
variables. We developed a multivariable logistic regression
model to predict the outcome of interest, defined as death or LT
by the end of 2013. Covariates that were significantly associated
to the outcome in 2013 (p value b0.25) with univariate analysis
were considered for the multivariable logistic regression model.
A forward stepwise selection process was used to select the
subset of variables independently associated with the outcome.
The predictors retained in the final model were combined into
a prognostic score to easily estimate the individual risk of death
or LT within 3 years. To this end, continuous predictors were
transformed into categorical variables according to clinically
relevant thresholds. The contribution of each predictor to the
prognostic score was proportional to its regression coefficient. To
help the clinician to easily obtain the prognostic score and the risk
of death or LT in a 3-year period using the patient characteristics,
a nomogram was provided.
2.5. Model performances
Performances of the developedmodel and the prognostic score
were investigated in terms of discrimination and calibration.
Discrimination assesses how well the model can distinguish
patients with the outcome of interest and patients without. This
was evaluated using the c-statistic, also known as the area under
the receiver operating characteristic curve [5]. The calibration
compares the observed proportion of events against the predicted
probabilities. It was evaluated using the Hosmer-Lemeshow test
[15]. These performances were tested for both the developed
model and the prognostic score, on each imputed dataset.
2.6. Model internal validation
To avoid overestimation of the model performances, we
performed an internal validation using a 10-fold cross-validation.
Overestimation happens when the model performs well on the
data used for development but not on test data. Cross-validation
can help detect overestimate models and helps to assess how well
the model fits new observations. We randomly partitioned the
initial dataset into 10 subsamples, fitted the model on nine of
the subsamples and evaluated its performances on the other. We
repeated this ten times, leaving out each subsample once. The
performance of the prognostic score was evaluated using the
Table 1
Characteristics of 2096 adult CF patients in 2010 according to vital status on December 31st 2013.
Patient characteristics Missing data (%) Total
n = 2096 (%)
Alive without LT
n = 1828 (%)
Death or LT
n = 268 (%)
p value
Gender, Male 0 1101 (52.5) 960 (52.5) 141 (52.6) 1
CFTR genotype 0 b0.001
Classes 1–3 1373 (65.5) 1165 (63.7) 208 (77.6)
Classes 4/5 254 (12.1) 238 (13.0) 16 (6.0)
Classes unknown 469 (22.4) 425 (23.3) 44 (16.4)
Airway colonization 0 2013 (96.0) 1747 (95.6) 266 (99.3)
Achromobacter xylosoxidans 0 133 (6.6) 98 (5.6) 35 (13.2) b0.001
Aspergillus fumigatus 0 641 (31.8) 556 (31.8) 85 (32.0) 0.02
Burkholderia cepacia 0 69 (3.4) 51 (2.9) 18 (6.8) b0.001
Non-tuberculous mycobacteria 0 95 (4.7) 79 (4.5) 16 (6.0) 0.009
Pseudomonas aeruginosa 0 1319 (65.5) 1102 (63.1) 217 (81.6) b0.001
Staphylococcus aureus 0 1290 (64.1) 1136 (65.0) 154 (57.9) 0.001
Stenotrophomonas maltophilia 0 203 (10.1) 166 (9.5) 37 (13.9) 0.001
Comorbidities 0 2007 (95.8) 1741 (95.2) 266 (99.3) 0.004
Cirrhosis 0 98 (4.9) 77 (4.4) 21 (7.9) b0.001
Insulin-treated diabetes 0 343 (17.1) 256 (14.7) 87 (32.7) b0.001
Pancreatic insufficiency 0 1758 (87.6) 1504 (86.4) 254 (95.5) b0.001
Allergic bronchopulmonary aspergillosis 12 (0.6) 378 (18.9) 302 (17.5) 76 (28.7) b0.001
Hemoptysis 9 (0.4) 204 (10.2) 152 (8.8) 52 (19.5) b0.001
Pneumothorax 9 (0.4) 29 (1.5) 19 (1.1) 10 (3.8) b0.001
Depression 30 (1.4) 147 (7.3) 114 (6.6) 33 (12.6) b0.001
FEV1, % predicted
a 144 (6.9) 58.3 (39.4–79.8) 63.3 (44.9–82.3) 29.1 (22.2–36.3) b0.001
FVC, % predicted a 150 (7.2) 79.0 (62.2–95.2) 82.4 (67.0–97.7) 50.3 (38.6–60.6) b0.001
Age (years) a 0 25.5 (21–32.3) 25 (21–32) 26.5 (22–33) 0.02
Height (cm2) a 84 (4.0) 167 (160–173) 167 (160–173) 165.9 (160–172) 0.26
Weight (kg) a 63 (3.0) 56 (50–63) 57 (51–64) 51 (46–57) b0.001
BMI (kg/m2) a 92 (4.4) 20.2 (18.5–22.1) 20.4 (18.9–22.3) 18.4 (17.3–20.0) b0.001
Number of IV antibiotics courses/year a 22 (1.0) 1 (0–2) 1 (0–2) 3 (2–5) b0.001
Number of IV antibiotics days/year a 76 (3.6) 14 (0–30) 0 (0–28) 45 (21–75) b0.001
Number of days of hospitalization/year a 327 (15.6) 0 (0–23) 0 (0–1) 2 (1–3) b0.001
Azithromycin 10 (0.5) 1254 (59.8) 1056 (58.1) 198 (74.2) b0.001
Non-invasive ventilation 11 (0.5) 127 (6.1) 51 (2.8) 76 (28.5) b0.001
Long-term oxygen therapy 11 (0.5) 230 (11.0) 97 (5.3) 133 (49.8) b0.001
Oral corticosteroids 13 (0.6) 171 (8.2) 125 (6.9) 46 (17.3) b0.001
Inhaled therapies 0 1873 (89.4) 1618 (88.5) 255 (95.1) 0.001
Inhaled antibiotics 0 1122 (59.9) 928 (57.4) 194 (76.1) b0.001
Inhaled corticosteroids 0 1012 (54.0) 868 (53.6) 144 (56.5) 0.003
FEV1%: forced expiratory volume in 1 s as percentage of predicted values.
FVC %: forced vital capacity as percentage of predicted values.
BMI: body mass index.
IV: intravenous.
CFTR: cystic fibrosis transmembrane conductance regulator.
LT: lung transplantation.
a Continuous variables, median (interquartile range).
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imputed datasets and we averaged all the values of c-statistic to
produce a single estimation of it.
2.7. Sensitivity analysis
A total of 184 patients lost to follow-up have been excluded
from the analysis. In order to provide the lack of impact of this
exclusion on the model, we reanalyzed the data including these
patients after imputation of their outcome.
The two outcomes (death without LT and occurrence of LT)
may be predicted by different covariates. We further investigated
if the use of the separate outcomes altered the interpretation, by
reanalyzing our data using each individual component.All statistical analyses were performed using R software
version 3.3.1.
3. Results
3.1. Data description
There were 2096 patients in the French CF Registry who
satisfied the study criteria. A total of 268 (13%) died or received LT
within the 3-year follow-up period, including 55 deaths without LT
and 213 transplantations. Patient characteristics according to death
or LT at 3 years are provided in Table 1. Significant differences in
baseline characteristics were observed between patients who died
or received LT during the 3-year follow-up period and those who
2615 patients alive and aged 18 years or 
older on 31st December 2010
2431 patients seen after 2010 with a known 
vital status on 31st December 2013 
335 patients transplanted before 2010
184 patients lost to follow-up
2096 patients considered for the analysis 
Fig. 1. Patients selection in the French CF Registry on 31st December 2010.
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patients at death or LT was 26.5 (22–33) years. Patients who died
or received LT had lower BMI, FEV1 and forced vital capacity
(FVC), and had higher rates of airway microbial colonization than
patients who remained alive without LT.
Patients who died or received LT were more likely to have
been diagnosed with ABPA, hemoptysis, pneumothorax, insulin-
treated diabetes, liver cirrhosis and depression. Treatment burden
was also higher in these patients with higher rates of long-term
oxygen therapy, non-invasive ventilation, oral corticosteroids,
azithromycin and higher number of days with intravenous (IV)
antibiotics and hospitalization.
3.2. Model development
The results of themultivariable logistic regression obtained after
forward selection for variables associated with death or LT are
shown in Table 2. The predictive model included 3 predictors
directly related to the patient clinical characteristics in particular:
FEV1, BMI and Burkholderia cepacia colonization. It also
identified 5 therapeutic variables, namely oral corticosteroids,
long-term oxygen therapy, non-invasive ventilation, number of IV
antibiotics courses per year and number of days of hospitalization
per year. The risk of death or LTwas higher for patients with lower
values of FEV1, BMI or with Burkholderia cepacia colonization.Table 2
Logistic regression model for prediction of within 3-year death or lung
transplantation in adults with CF.
Odds ratio (95% CI) p value
FEV1, % predicted 0.94 (0.92–0.95) b0.001
BMI (kg/m2) 0.87 (0.81–0.93) b0.001
Burkholderia cepacia colonization 0.007
Test negative 1
Test positive 3.15 (1.55–6.41)
No test 1.17 (0.23–5.93)
Number of intravenous antibiotics courses/year 1.16 (1.07–1.26) b0.001
Number of days of hospitalization/year 1.17 (1.06–1.28) 0.001
Oral corticosteroids 2.05 (1.25–3.35) 0.004
Long-term oxygen therapy 2.81 (1.83–4.32) b0.001
Non-invasive ventilation 1.74 (1.01–3.00) 0.04Furthermore, the risk of death or LT within 3 years increased with
number of days of hospitalization per year, number of IV
antibiotics courses per year, the use of oral corticosteroids, long-
term oxygen therapy and non-invasive ventilation. The Hosmer–
Lemeshow test for this model showed good agreement between the
predicted and observed values on 95% of the imputed datasets. The
average c-statistic of the model across the imputed datasets was
0.91 (95% CI: 0.89–0.93). The model was correctly specified and
had an excellent ability to distinguish individuals who experienced
the outcome, and those who did not.
Furthermore, we considered the rate of decline in FEV1 before
2010 as a potential predictor. For each subject, this was estimated
by using a linear mixed model with a random intercept and linear
slope. The rate of decline of FEV1 before study entry was not a
better predictor than the value of FEV1 at the study entry. Thus, it
was not considered further.
3.3. Prognostic score
We developed a prognostic score, which was a weighted
score calculated from the 8 predictors (Table 2). The parameters
of the model were reestimated after transforming continuous
variables into categorical variables according to clinically relevant
thresholds. A value proportional to each estimated parameter was
added to the score (Table 3).
Fig. 2 illustrates a nomogram which facilitates the use of the
predictive model and the calculation of the prognostic score for
each CF patient, given his or her characteristics. The nomogram
provides a score value according to the scale given at the top of
the figure. All the scores calculated for the eight predictors are
then summed to obtain the prognostic score of the patient. The
risk of death or LT corresponding to the prognostic score is given
by the scale at the bottom of the figure.
A logistic regression using only the prognostic score as
predictor of death or LT provided an odds ratio of 2.75 (95%CI
2.47–3.06, p value b10−3). The risk of death or LT was greater
for higher scores. The fitting of the prognostic score provided
an average discriminant ability of 0.91 (95% CI: 0.89–0.92)
which indicated good discriminative ability, and thus supports the
use of this score to predict death or LT in a 3-year period. The
Hosmer–Lemeshow test indicated that there were no significant
differences between the prognostic score's predictions and the
observed values on all the imputed datasets. These results were
confirmed with the cross-validation of the prognostic score,
which provided a c-statistic of 0.90 (95% CI: 0.88–0.93).
3.4. Classes of score
Based on risk of death or LT, we classified patients into three
groups with low, intermediate and high risk (see Supplementary
Fig. 1 for detailed risk of death or LT at each level of the score).
From the score 0 to 1.5, the percentages of death or LT were
lower than 2%. From the score 2 to 3.5, the percentages of death
or LT were ranged between 7% and 15%. Finally, for the scores
higher or equal to 4, the percentages of death or LT were ranged
between 33% and 100%. Using the above distribution of death or
LT in each value of the score, we created three risk groups. In the
Table 3
Risk score for prediction of within 3-year death or lung transplantation in adults with CF.
Coefficient Odds ratio (95% CI) p-value Score
FEV1, % predicted b10
−3
N = 60 0 1 0
[30–60] 1.60 4.97 (2.53–9.74) 1.5
b30 2.99 19.91 (9.79–40.49) 3
BMI (kg/m2) b10−3
N = 18.5 0 1 0
[16–18.5] 0.70 2.01 (1.41–2.86) 0.5
b16 1.21 3.36 (1.62–6.97) 1
Burkholderia cepacia colonization 0.01
Test negative 0 1 0
Test positive 1.08 2.96 (1.45–6.03) 1
No test -0.10 0.90 (0.19–4.35) 0
Number of intravenous antibiotics courses/year b10−3
0 0 1 0
[1-2] 0.61 1.84 (1.07–3.18) 0.5
N2 1.37 3.92 (2.29–6.72) 1
Hospitalization (yes vs no) 0.33 1.39 (0.95–2.03) 0.09 0.5
Oral corticosteroids (yes vs no) 0.80 2.20 (1.35–3.58) 10−3 1
Long-term oxygen therapy (yes vs no) 1.12 3.08 (2–4.73) b10−3 1
Non-invasive ventilation (yes vs no) 0.69 1.99 (1.16–3.42) 0.01 1
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low risk of death or LT (1%) at 3 years. The second group (score
[2–3.5]) corresponded to patients at moderate risk of death or LT
(10%) at 3 years. Lastly, the highest group (score ≥ 4) identified
patients with a very high risk of death or LT (55%) at 3 years
(Fig. 3).3.5. Comparison between the prognostic score and its components
We compared the diagnostic accuracy of the prognostic
score with the one provided by each of its components. The
discriminant ability of the prognostic score (c-statistic 0.91, 95%
CI: 0.89–0.92) was significantly higher than the one provided byFig. 2. Nomogram designed to estimate risk of death or lung transplantation. To
corresponding risk of death or LT of a given patient. The patient is an 18 years old fem
inclusion of 20.57 kg/m2 (0 point). She had 2 IV antibiotics courses in the year 20
therapy (0 point), no non-invasive ventilation (0 point), no colonization with Burkhol
These clinical characteristics correspond to a total of 2 points and a risk of death o
estimated at 4%.each of its components. In particular, it was significantly higher
than the discriminant ability obtained with the criterion of
FEV1 b 30% for LT eligibility (c-statistic 0.74, 95% CI: 0.71–
0.77) (see Supplementary Table 2 for details).3.6. Sensitivity analyses
The model obtained after imputation of the outcome of
patients lost to follow-up included the same predictors as the
model excluding patients lost to follow-up. The characteristics at
baseline of these lost to follow-up patients lead us to believe that
they were patients with a low risk of death or LT (Supplementary
Table 3). Using our prognostic score, we obtained their mediandisplay the application of the nomogram, we calculated the score and the
ale gender with a FEV1 at inclusion of 54% predicted (1.5 points) and a BMI at
10 (0.5 points). She had no oral corticosteroids (0 point), no long-term oxygen
deria cepacia (0 point) and no days of hospitalization in the year 2010 (0 point).
r LT of 0.04. Thus, the expected risk of death or LT within the next 3 years is
Fig. 3. Three-year risk of death or lung transplantation according to proportion
of events in each score.
707L. Nkam et al. / Journal of Cystic Fibrosis 16 (2017) 702–708(interquartile range) score: 0.5 (0–1.5), indicating a low risk of
death or LT at 3 years.
Next, we examined the impact of having chosen a composite
outcome (occurrence of LT or death without LT) versus analyzing
them as separate outcomes. The results of these analyses are
presented in Tables 4 and 5 Supplementary materials respectively.
Factors associated with LT were remarkably comparable with
those obtained for the composite outcome. Factors associated
with death without LT likely reflected some of the relative
contraindications to transplant (for example cirrhosis, older age,
Burkholderia cepacia colonization), but no treatment-associated
variables.4. Discussion
We used the most recent data from the French CF Registry
to identify current prognostic factors in adults with CF. Eight
risk factors were associated with death or LT within 3 years for
adults: FEV1, BMI, Burkholderia cepacia colonization, number of
IV antibiotics courses per year, number of days of hospitalization
per year, use of long-term oxygen therapy, non-invasive ventilation
and use of oral corticosteroids. These factors were combined in a
single prognostic score which showed good performance in
terms of calibration and discrimination. This score allowed the
identification of three groups of patients with markedly different
risks of poor outcomes: from the lowest to the highest group,
there was more than a 50-fold increase in the risk of death or LT.
Importantly, the developed score was better at predicting the
risk of death or LT than its individual components (especially
FEV1 b 30%), confirming the multidimensional nature of
disease severity in CF. These findings confirm data by George
et al. who suggested that FEV1 b 30% predicted is not by itself
sufficient for the identification of patients at risk of poor outcome
(i.e., LT or death without LT) in the modern era of CF care [12].
It extends these data by identifying important variables to poor
outcomes in adults CF patients and by combining them in a
clinically usable score.
Our goal was to examine prognostic factors associated with
poor outcomes in adult CF patients, leading to the choice of a
combined outcome defined as death without LT or occurrence
of LT. Although older studies, which were performed at a time
when LT was less developed, have focused on death without
considering LT, the choice of studying a combined outcome of
death without LT or occurrence of LT was also used in previousstudy [21]. As sensitivity analyses, we reanalyzed our data using
the occurrence of LT and death without LT as separate outcomes.
The findings obtained when considering the occurrence of LT as
the primary outcome were quite close to those obtained when
considering the composite outcome, largely reflecting the fact
that 80% of the patients in the combined outcome underwent
a LT. Focusing only on death without LT would have biased
our analyses towards patients with relative contraindication to
transplant and considerably reduced the usefulness of our score,
which is intended to be used in all adult patients with CF. Thus,
the use of the composite outcome of death without LT or the
occurence of LT appeared appropriate in the present era when LT
has become the standard of care in CF patients with refractory
respiratory insufficiency.
The present study has several strengths. Analyses were
performed using data from the French CF Registry that covers
around 90% of French CF patients. Our model was developed
using a large variety of covariates considered as potential
predictors of poor outcome in patients with CF. The continuous
variables included in the prognostic score were categorized using
predetermined (based on clinical knowledge) cut-offs, which
appeared easier for use in daily practice. The study focused on
adults with CF because death from CF in children is now very
rare in developed countries [26], and because over 95% of LT
in France are performed in adults. Missing covariates data, a
common issue in observational studies, were handled using the
multiple imputation approach, which helped to minimize data loss,
avoid biased estimates, and provide better estimations [24]. We
also recognize limitations to the present study. Some covariates,
such as professional status and marital status, available in the
French CF Registry were not included in the models because of
a high percentage of missing data. Additionally, variables not
collected in the French CF Registry such as physical activity and
exercise capacity, pulmonary hemodynamics [22,28] may also be
important in assessing the prognosis of CF adults. On the other
hand, these variables may not be routinely obtained in all CF
patients, and thus may not be appropriate for inclusion in a score
designed for referring patients for specialized evaluation for LT.
Patients who received combined lung-liver transplantation during
the follow-up were considered as having an outcome, whereas
patients who received isolated liver transplantation during the
follow-up were not considered as having a poor outcome. Because
isolated liver transplantation was performed in a very small
number of patients (as less than 5 patients per year received liver
or lung/liver transplantation), this choice was unlikely to alter
our conclusions. The 184 patients who were lost to follow-up
(i.e., those with an unknown outcome at the end of the study) were
excluded from the analyses. Analyses of the clinical characteristics
of these patients suggested that, most patients lost to follow-up
were those with milder disease and were at very low risk of
death or LT. Additionally, sensitivity analyses suggested that the
exclusion of these patients had only limited impact on our results.
The vital status of patients corresponded to the one at the end of the
year, and the use of annual data did not exclude the possibility that
the prognosis could have changed considerably between the last
visit and the end of the year. Lastly, the prognostic score included
variables related to the patient's status (FEV1, BMI, Burkholderia
708 L. Nkam et al. / Journal of Cystic Fibrosis 16 (2017) 702–708cepacia) and also variables related to therapeutic interventions
(hospitalization, IV antibiotics, oral corticosteroids, non-invasive
ventilation, long-term oxygen therapy) that rely on physician
choices. Future studies should aim address the validity of this
score in other countries with different healthcare systems.
Additionally, the value of assessing longitudinal changes (e.g.,
related to treatment modifications) in the score in individual
patients should be evaluated in the future.
The prognostic score was built after reevaluation of prognostic
factors in adult patients with CF, to predict the risk of death or LT
in a 3-year period. This score showed good performance and was
significantly better in terms of discrimination than its compo-
nents, including the criterion of FEV1 lower than 30% proposed
for LT eligibility. If validated in other settings, this score could be
a useful tool in the future for selecting patients requiring an
evaluation for LT.
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